Posts by Sandra Ansanay-Alex
Onward Confirms Amazing Results to restore Arm and Hand Function in People With Spinal Cord Injury
The Up-LIFT study evaluating ARC-EX Therapy demonstrated the effectiveness of the device to improve extremity strength and function in people with movement disabilities. The Up-LIFT study The Up-LIFT study is a prospective, single-arm pivotal study designed to evaluate the safety and effectiveness of non-invasive electrical spinal cord stimulation (ARC-EX Therapy) to treat upper extremity…
Read MoreSelexis and NexImmune Sign an Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers
This Agreement supports the development of molecules targeting acute myeloid leukemia, multiple myeloma, human papillomavirus (HPV) associated tumors, and additional human leukocyte antigens (HLAs) that have the potential to increase immunotherapy options for patients Selexis SA, a JSR Life Sciences company based in Geneva Switzerland, and NexImmune Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company…
Read MoreDebiopharm Innovation Funds invests to accelerate the development of genomics medicines via technology powered AI
The strategic investment arm of Swiss biopharmaceutical company Debiopharm wants to reduce biotherapies’ development time and cost using AI (Artificial Intelligence) Debiopharm Innovation Fund announced an investment in Whitelab Genomics alongside French Venture Capital company, Omnes Capital, in a $10 Million Series A Round to advance their mission to accelerate the development of genomics medicines…
Read MoreTop 100 Swiss Startups 2022: the Life Sciences Winners
17 Western Switzerland Life Sciences startups in biotech, medtech and foodtech were selected The TOP 100 Swiss Startup Award 2022 celebrated Switzerland’s most promising startups. The 12 edition winners were announced on 7 September 2022. Congratulations to all the Western Switzerland and their amazing project that were celebrated this year. Geneva Stalicla SA (41)…
Read MoreNovartis invests CHF 100 million in Basel
A new state-of-the-art biologics centre Novartis announced plans to invest around CHF 100 million in the development of next-generation biotherapeutics at its Basel campus. The plan is to build a new state-of-the-art biologics centre for early technical development, which will replace an existing facility in the Klybeck area by 2026. Position Novartis at…
Read MoreNew Gene Therapy Laboratory at the Biofactory Competence Center (BCC) in Fribourg
A jewel for biopharmaceutical education and research The Biofactory Competence Center (BCC) in Freiburg inaugurated its new gene therapy laboratory on Wednesday 7 September 2022. This state-of-the-art facility will meet the growing needs of the Swiss biopharmaceutical industry in terms of the training of specialised staff and the production of drugs. Thanks to a…
Read MoreForum des 100 – Le Temps
Two BioAlps experts nominated Two Life Sciences experts, Dominique Truchot-Cardot and Alexandre Pauchard, are among the 100 personalities of the year in French-speaking Switzerland and have been selected by Le Temps Magazine for the Forum des 100. The conference will take place on 11 October 2022 at the Swiss Tech Convention Center. Dominique…
Read MoremachineMD raises CHF 3.2 Million
The MedTech startup is developing a medical device for the early diagnosis of neurological disorders including brain tumors via neuro-ophthalmic examinations. machineMD, from the Sitem StartUp Club (SSC), is a spin-off of the University Hospital of Bern, Inselspital, founded by Prof. Mathias Abegg, MD, PhD, and a team of entrepreneurs and medical device experts.…
Read MoreBiopôle Vanguard Accelerator
This six-month programme, supported by Biopôle SA and its partners, helps health-oriented projects to grow. The Vanguard Accelerator is a free six-month programme, run by Biopôle SA and its partners, to help digital-health-oriented projects supercharge their innovation and take their business strategy to the next level. This immersive programme is a unique opportunity for early-stage…
Read MoreCHUV, HUG and Inserm help Down syndrome patients to get better
The injection of the hormone GnRH improved the cognitive functions of several Down syndrome patients An Inserm team within the Lille neuroscience & cognition laboratory (Inserm/University of Lille/CHU of Lille), the Centre Hospitalier Universitaire Vaudois (CHUV) and The Hôpitaux Universitaires de Genève (HUG) have collaborated to test the efficacy of a therapy based on…
Read More